The Fly

Cross Country Healthcare price target raised to $45 from $41 at Barrington

Barrington analyst Kevin Steinke raised the firm’s price target on Cross Country Healthcare to $45 from $41 and keeps an Outperform rating on the shares. The analyst notes the company’s Q3/2022 results exceed recently increased guidance. The demand environment remains favorable due to the extremely tight healthcare labor market, Steinke adds, pointing out that growth also continues to benefit from the significant investments that Cross Country has made in recruiter productivity and capacity.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CCRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More